European Journal of Cancer
Volume 39, Issue 17 , Pages 2439-2449 , November 2003

Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials

  • G Atalay

      Affiliations

    • Institut Jules Bordet, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    • ,
  • L Biganzoli

      Affiliations

    • Institut Jules Bordet, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    • ,
  • F Renard

      Affiliations

    • Institut Jules Bordet, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    • ,
  • R Paridaens

      Affiliations

    • Universitair Ziekenhuis Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    • ,
  • T Cufer

      Affiliations

    • Institute of Oncology, Zaloska 2SL-1000 Ljubljana, Slovenia
    • ,
  • R Coleman

      Affiliations

    • Weston Park Hospital NHS Trust, Whitham Road, Sheffield, S10 2SJ, UK
    • ,
  • A.H Calvert

      Affiliations

    • Newcastle General Hospital, Westgate Road, Newcastle Upon Tyne, NE4 6BE, UK
    • ,
  • T Gamucci

      Affiliations

    • Ospedale SS Trinita, Località San Marciano 039 Saro, Italy
    • ,
  • A Minisini

      Affiliations

    • Institut Jules Bordet, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    • ,
  • P Therasse

      Affiliations

    • EORTC Data Center, Av E Mounier 83, Brussels, Belgium
    • ,
  • M.J Piccart

      Affiliations

    • Institut Jules Bordet, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32-2-541-3206; fax: +32-2-538-0858
    • ,
  • on behalf of the EORTC Breast Cancer and Early Clinical Studies Groups

Received 3 April 2003 ,Accepted 4 April 2003.

References 

  1. Miller KD, Sledge GW. The role of chemotherapy for metastatic breast cancer. Hematol. Oncol. Clin. North Am. 1999;13:415–434
  2. Stockler M, Wilcken NR, Ghersi D, et al.  Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat. Rev. 2000;6:151–168
  3. Rahman ZU, Frye DK, Smith TL, et al.  Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. A reference. Cancer. 1999;85:104–111
  4. Horthobagyi GN. Can we cure limited metastatic breast cancer?. J. Clin. Oncol. 2001;20:620–623
  5. Bergh J, Jönsson P, Glimelius B, et al.  A systemic overview of chemotherapy effects in breast cancer. Acta Oncol. 2000;40:253–280
  6. Cristofanilli M, Hortobagyi GN. New horizons in treating metastatic breast cancer. Clin. Breast Cancer. 2001;1:276–287
  7. Tomiak E, Piccart M, Mignolet F, et al.  Characterization of complete responders to combination chemotherapy for advanced breast cancer (a retrospective EORTC Breast Group study). Eur. J. Cancer. 1996;32A:1876–1887
  8. Greenberg PA, Hortobagyi GN, Smith TL, et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 1996;14:2197–2205
  9. Swenerton KD, Legha SS, Smith T, et al.  Prognostic factors in metastatic breast cancer treated with combination cheotherapy. Cancer Res. 1979;39:1552–1562
  10. Hortobagyi GN, Smith TL, Legha SS, et al.  Multivariate analysis of prognostic factors in metastatic breast cancer. J. Clin. Oncol. 1983;1:776–786
  11. George SL, Hoogstraten B. Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J. Natl. Cancer Inst. 1978;60:731–736
  12. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: De Vita ,  Hellman S,  Rosenberg SA editor. Cancer. Principles and Practice of Oncology. 4th edn.. Philadelphia: Lipincott Company; 1993;p. 1264–1332
  13. Perez JE, Machiavelli M, Leone BA, et al.  Bone-only versus visceral-only metastatic pattern in breast cancer (analysis of 150 patients. A GOCS study. Grupo Oncologico Cooperativo del Sur). Am. J. Clin. Oncol. 1990;13:294–298
  14. Leone BA, Romero A, Rabinovich , et al.  Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am. J. Clin. Oncol. 1988;11:618–622
  15. Nash CH, Jones SE, Moon TE, et al.  Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer. 1980;46:2380–2388
  16. Muss HB. Endocrine therapy for advanced breast cancer (a review). Breast Cancer Res. Treat. 1992;21:15–26
  17. Santen RJ, Manni A, Harvey H, et al.  Endocrine treatment of breast cancer in women. Endocr. Rev. 1990;11:221–265
  18. Dunphy FR, Spitzer G, Fornoff JE, et al.  Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994;73:2157–2167
  19. Rowlings PA, Antman KS, Horowitz MM, et al.  Prognostic factors in autotransplants for metastatic breast cancer. Blood. 1995;86:618; a
  20. Rizzieri DA, Vredenburgh JJ, Jones RR, et al.  Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J. Clin. Oncol. 1999;17:3064–3074
  21. Pritchard KI. Liver metastases (can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management?). Eur. J. Cancer. 1997;33(Suppl. 7):S11–S14
  22. Allegra JC, Lippman ME, Thomson EB, et al.  Disribution, frequency and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 1979;39:1447–1454
  23. Patanaphan V, Salazar OM, Risco R. Breast cancer:metastatic patterns and their prognosis. South Med. J. 1988;81:1109–1112
  24. Qazi R, Chuang J-LC, Drobyski W. Estrogen receptors and the pattern of relapse in breast cancer. Arh. Intern. Med. 1984;144:2365–2367
  25. Campbell FC, Blamey RW, Elston CW, et al.  Oestrogen receptor status and sites of metastases in breast cancer. Br. J. Cancer. 1981;44:456–459
  26. Jardines L, Callans LS, Torosian MH. Recurrent breast cancer (presentation, diagnosis, and treatment). Semin. Oncol. 1993;20:538–547
  27. Zinser JW, Hortobagyi GN, Buzdar AU, et al.  Clinical course of breast cancer patients with liver metastases. J. Clin. Oncol. 1987;5:773–782
  28. O'Reilly SM, Richards MA, Rubens RD. Liver metastases from breast cancer (the relationship between clinical, biochemical and pathological features and survival). Eur. J. Cancer. 1990;26:574–577
  29. Hoe AL, Royle GT, Taylor I. Breast Liver Metastases-incidence, diagnosis and outcome. J. Royal Soc. Med. 1991;84:714–716
  30. Paridaens R, Biganzoli L, Bruning P, et al.  Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer (a European Organization for Research and Treatment of Cancer Randomized Study with cross-over). J. Clin. Oncol. 2000;18:724–733
  31. Biganzoli L, Cufer T, Bruning P, et al.  Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer (the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III trial). J. Clin. Oncol. 2002;20:3114–3121
  32. Fumoleau P. Treatment of patients with liver metastases. Anticancer Drugs. 1996;7(Suppl. 2):21–23
  33. Coleman RE, Howell A, Eggleton SPH, Maling SJ, Miles DW. Phase II study of docetaxel in patients with liver metastases from breast cancer. Ann. Oncol. 2000;11:541–546
  34. Chan S, Friedrichs K, Noel D, et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J. Clin. Oncol. 1999;17:2341–2354
  35. Nabholtz JM, Falkson G, Camps D, et al.  A phase III trial comparing doxorubicin and docetaxel (AT) to doxorubicin and cyclophosphamide (AC) as first line CT for MBC. Proc. Am. Soc. Clin. Oncol. 1999;18:127a; (abstr 485)
  36. Nabholtz JMA, Reese DM, Lindsay MA, et al.  Docetaxel in the tretament of breast cancer (an update on recent studies). Semin. Oncol. 2002;29:28–34
  37. French Epirubicin Study Group . A prospective randomised phase II comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J. Clin. Oncol. 1988;6:679–688
  38. Raab R, Nussbaum KT, Behrend M, Weiman A. Liver metastasis of breast cancer (results of liver resection). Anticancer Res. 1998;18:2231–2234
  39. Selzener M, Morse MA, Vredenburgh JJ, et al.  Liver metastases from breast cancer (long-term survival after curative resection). Surgery. 2000;127:383–389
  40. Carlini L, Lonardo MT, Carboni F, et al.  Liver metastases from breast cancer. Results of surgical resection. Hepatogastroenterology. 2002;49:1597–1601
  41. Elias D, Lasser PH, Montrucolli D, et al.  Hepatectomy for liver metastases from breast cancer. Eur. J. Surg. Oncol. 1995;21:510–513
  42. Livraghi T, Goldberg SN, Solbiati L, et al.  Percutaneous radio-frequency ablation of liver metastases from breast cancer (initial experience in 24 patients). Radiology. 2001;220:145–149
  43. Tekin K, Kocaoglu H, Bayar S. Long-term survival after regional chemotherapy for liver metastases from breast cancer. Tumori. 2002;88:167–169
  44. Nieto Y, Nawaz S, Jones RB, et al.  Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J. Clin. Oncol. 2002;20:707–718
  45. Holmes FA, Buzdar AU, Kau SW, et al.  Combined modality approach for patients with isolated recurrences of breast cancer (IV-NED) (The M.D. Anderson experience). Breast Dis. 1994;7:7–20
  46. Rivera E, Holmes FA, Buzdar AU, et al.  Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002;8:2–9

PII: S0959-8049(03)00601-4

doi: 10.1016/S0959-8049(03)00601-4

European Journal of Cancer
Volume 39, Issue 17 , Pages 2439-2449 , November 2003

Article Tools

* Image Usage & Resolution